![]() This was the first time evidence has documented a cure for the herpes simplex virus. The study was able to validate that for some participants there was a noted progression from a positive antibody serology to a negative one. Antiviral activity of the 5CC against HSV-1 and HSV-2 was tested on RC-37 cells in vitro using a plaque reduction assay. A longitudinal approach was adopted over 6 months, where participants' infection rates were measured at various points during the treatment. ![]() A randomized, investigator-blinded method was performed on patients with a moderate to high positive concentration of herpes serum antibodies. The study also focused on the immune-inhibiting properties of the 5CC which indicated cell membrane breakdown and eradication. For the first time, this study highlighted the combinations capacity to act by preventing cell-to-cell infection to suppress the activity of the virus. Testing was performed using 5CC with immunotherapeutic features to be able to neutralize herpes viral activity inside the human body. The aim of this study was to explore alternative substitutes to treat herpes simplex virus infection and prevent viral reproduction where conventional medications had previously failed. These 5CC are effective inhibitors of herpes viral DNA synthesis and interferon (IFN)-induced cellular antiviral response and were found to neutralize antiviral reproduction by blocking cell-to-cell infection. The treatment consisted of five immunotherapeutic core compounds (5CC) comprising of Rhodiola, Tribulus, Astragalus, Lysine and a proprietary Amino Acid Formula. Their study served to investigate a relatively novel approach to breaking down the herpes viral envelope by employing specific T Cells generated through a particular Amino Acid formula. Existing options include antivirals that have been approved for clinical administration and a limited number of nucleoside analogues.Ī recent study by Synergy Pharmaceuticals ( in association with ACU may set a new stream of thought on the topic by bringing back traditional medicine as an opportunity to make a difference. Alarming figures especially when coupled with the increased risk for pregnant women, newborn babies and with the incidence of herpes encephalitis on the rise. The United States alone reports over 750,000 new cases of herpes infections every year. Andrews is affiliated with Stetson University.Sydney, Aus, (ACN Newswire) - There is an immediate need for alternative treatments to combat the spread of Herpes type 1 & 2 strains. With a new chief executive officer, Trulance sales beginning to accelerate, and other products moving through the FDA approval process, Synergy needed to decide whether to stay the course and become a full-fledged pharmaceutical company or seek a partner and stick to its research and development competency. In September 2018, the company was heavily indebted and the stock was priced below US$2 many wondered if Synergy had been right to go it alone or if it should continue that strategy for developing the lucrative North American market. ![]() The company had not partnered with a larger pharmaceutical company during the regulatory review process, which was typical for smaller drug development companies, and as a result, it retained 100 per cent of the sales revenue but had virtually no in-house sales or marketing capability. Synergy now needed to scale up from a research-and-development shop to a sales-and-marketing powerhouse. (Synergy) received marketing approval from the US Federal Drug Administration (FDA) for its first drug, Trulance, which targeted a large market that had only two other approved competitors. After more than a decade of development, US-based Synergy Pharmaceuticals Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |